Publications by authors named "Sheng-Fei Qin"

Cancer stem cells (CSCs) are crucial in the pathogenesis of human cancers. Existing studies reported that microRNA (miRNA) modulates the stemness of CSCs. We discovered that renal cell CSCs have suppressed miR-381.

View Article and Find Full Text PDF

Background: As a new-generation androgen-receptor antagonist, enzalutamide is a first-choice drug for advanced prostate cancer (PCa) patients. However, secondary resistance to enzalutamide poses a new challenge in the treatment of cancer. Long non-coding RNA (lncRNA) regulates cell function through many levels and mechanisms, and also plays an important role in the biological behaviors of tumors.

View Article and Find Full Text PDF

Hypoxia-induced erythropoietin signaling plays an important role in tumor growth and invasion. In the present study, we investigated the contribution of erythropoietin signaling pathway to castration-resistant prostate cancer and the development of a neuroendocrine phenotype. Immunohistochemical staining showed that the erythropoietin and erythropoietin receptor scores in castration-resistant prostate cancer and androgen-dependent prostate cancer were 7.

View Article and Find Full Text PDF

Synopsis of recent research by authors named "Sheng-Fei Qin"

  • - Sheng-Fei Qin's research focuses on the molecular mechanisms of cancer stem cells and resistance to therapies in renal and prostate cancers, highlighting the roles of microRNAs and long non-coding RNAs in these processes.
  • - One significant finding is that miRNA-381 regulates renal cancer stem cell properties and their resistance to sunitinib by targeting SOX4, indicating a potential therapeutic target for overcoming drug resistance in renal cancer.
  • - Additionally, his studies reveal that the lncRNA NONHSAT210528 promotes proliferation and invasion in enzalutamide-resistant prostate cancer, and the erythropoietin signaling pathway contributes to the progression of castration-resistant prostate cancer, suggesting new avenues for targeted treatments.